Regular ArticleComparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome☆
Section snippets
Subjects
Thirty-six patients with unstable angina pectoris or non-ST-elevation myocardial infarction were included in the study. From each patient blood was sampled on four occasions: acute (sample 1, i.e. at admission to coronary care unit), 24 h after admission (sample 2), and 3 (sample 3) and 6 months (sample 4) after admission. During the course of the study two patients died and two withdrew from the study, one after the second sampling and one after the third sampling.
Patients with severe
Results
Statistically significant correlations (p < 0.01, N = 150) between the immunoassays and the functional assay were observed [r2 = 0.67 and 0.47 for Asserachrom and Haemochrom, respectively (Fig. 1). The regression functions were 0.64x + 21.6 and 0.65x + 11.7 for Asserachrom and Haemochrom, respectively. Of the three assays the Pefakit values were higher within the measurement interval than those of the immunoassays of which the Asserachrom gave higher results than the Haemochrom assay (Fig. 2). Since the
Discussion
The samples used in the present study are from a survey of hemostasis and inflammatory markers in patients with acute coronary syndrome in which e.g. the acute phase reactants fibrinogen and CRP are studied [18]. In the present report, we focus on the measurement of TAFI concentrations with assays based on different principles. The immunoassays measure the plasma concentration of total TAFI antigen or the pro-TAFI antigen, only, whereas the functional assay measures the TAFI activity
Conclusion
Our study shows that the virtual concentration and course of TAFI concentration changes during an acute coronary event and the convalescence depend on the measurement principle and method. The kinetic assay principle with high precision and easy performance speaks in favor of the chromogenic assay based on determination of TAFI activity concentration corresponding to the concentration of pro-TAFI. On the other hand, the availability of a traceable calibrator in the Asserachrom kit combined with
Acknowledgements
We are particularly grateful to Nida Soutami and Ingrid Jacobsson for their skilful performance of all analysis and Professor Margareta Blombäck for continued support and advice. We would also like to thank Barry Woodhams and Olivier Morboeuf from Diagnostica Stago for supplying Asserachrom kits and useful suggestions. The cost of one month's laboratory work (laboratory technician) was paid by Diagnostica Stago.
References (19)
- et al.
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
J Biol Chem
(1995) - et al.
Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
Blood
(2000) - et al.
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
Blood
(2004) - et al.
High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
J Thromb Haemost
(2005) - et al.
Very high TAFI antigen levels are associated with a lower hard core coronary events: the PRIME Study
J Thromb Haemost
(2003) Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis (review)
Clin Lab
(2003)- et al.
Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors
Arterioscler Thromb Vasc Biol
(2000) - et al.
Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke
Stroke
(2003) - et al.
Plasma procarboxypeptidase U in men with symptomatic coronary artery disease
Thromb Haemost
(2000)
Cited by (6)
Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome
2017, Medicina IntensivaCitation Excerpt :In fact, the reported serum levels of TAFI were ambiguous in coronary heart disease.5,6 The reasons for the difference of TAFI levels among researchers might can be explained as different cardiovascular disease stages15 or different assays or different antibody reactivity toward different TAFI isoforms.16 In present study, we found decreased serum TAFI level in ACS patients.
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor
2012, Thrombosis ResearchCitation Excerpt :Since TAFI inhibits tissue plasminogen activator-induced fibrinolysis, it has been suggested that high TAFI levels may be associated with increased risk of venous thromboembolism (VTE), VTE recurrence and arterial thrombosis; these results however were not confirmed in other studies [6–8]. Besides differences in populations, risk factors, timing of blood sampling in relation to disease and outcomes, these contradictory results may be related to the different TAFI assays used [9–11]. It has been reported that some ELISA methods are sensitive to certain polymorphisms of TAFI gene and have different reactivity towards different forms of TAFI [8].
Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?
2011, Thrombosis ResearchCitation Excerpt :Interestingly, a recent study suggested that reduced fibrinolytic capacity, as measured by a plasma-based tissue factor induced clot lysis assay, may be a risk factor for myocardial infarction in young men [24]. We have previously found that TAFI activity concentration is significantly elevated in ACS patients in the convalescence phase [25] and now with a larger sample size a significant difference between patients and controls was revealed also in the acute phase of the disease. An increased concentration of TAFI, being a fibrinolysis inhibitor, would be assumed to decrease the fibrinolysis.
Carboxypeptidase U (CPU, TAFIa, CPB2) in thromboembolic disease: What do we know three decades after its discovery?
2021, International Journal of Molecular SciencesImpaired fibrinolysis in angiographically documented coronary artery disease
2015, Advances in HematologyThe TAFI system: The new role of fibrinolysis
2007, Hamostaseologie
- ☆
Financial support for this investigation was obtained from the Heart and Lung Foundation Sweden, Stiftelsen Serafimerlasarettet, Karolinska Institutet foundation no. 176.